339 related articles for article (PubMed ID: 31550737)
1. Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project.
Pala A; Nadji-Ohl M; Faust K; Rückriegel S; Roder C; von der Brelie C; Forster MT; Löbel F; Schommer S; Löhr M; Renovanz M; Grübel N; Rothenbacher D; König R; Engelke J; Schmitz B; Wirtz CR; Ringel F; Senft C; Rohde V; Tatagiba M; Ernestus RI; Vajkoczy P; Ganslandt O; Nagel G; Coburger J
J Neurol Surg A Cent Eur Neurosurg; 2020 Jan; 81(1):48-57. PubMed ID: 31550737
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
Tom MC; Varra V; Leyrer CM; Park DY; Chao ST; Yu JS; Suh JH; Reddy CA; Balagamwala EH; Broughman JR; Kotagal KA; Vogelbaum MA; Barnett GH; Ahluwalia MS; Peereboom DM; Prayson RA; Stevens GHJ; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1099-1105. PubMed ID: 31022510
[TBL] [Abstract][Full Text] [Related]
4. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
5. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.
Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E
Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551
[TBL] [Abstract][Full Text] [Related]
6. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
[TBL] [Abstract][Full Text] [Related]
7. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
Huang RY; Young RJ; Ellingson BM; Veeraraghavan H; Wang W; Tixier F; Um H; Nawaz R; Luks T; Kim J; Gerstner ER; Schiff D; Peters KB; Mellinghoff IK; Chang SM; Cloughesy TF; Wen PY
Neuro Oncol; 2020 Dec; 22(12):1822-1830. PubMed ID: 32328652
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
[TBL] [Abstract][Full Text] [Related]
9. Quantitative texture analysis in the prediction of IDH status in low-grade gliomas.
Jakola AS; Zhang YH; Skjulsvik AJ; Solheim O; Bø HK; Berntsen EM; Reinertsen I; Gulati S; Förander P; Brismar TB
Clin Neurol Neurosurg; 2018 Jan; 164():114-120. PubMed ID: 29220731
[TBL] [Abstract][Full Text] [Related]
10. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
11. Intraoperative 3D ultrasound-guided resection of diffuse low-grade gliomas: radiological and clinical results.
Bø HK; Solheim O; Kvistad KA; Berntsen EM; Torp SH; Skjulsvik AJ; Reinertsen I; Iversen DH; Unsgård G; Jakola AS
J Neurosurg; 2019 Feb; 132(2):518-529. PubMed ID: 30717057
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
13. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
14. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
15. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
17. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status.
Zhao J; Wang YL; Li XB; Hu MS; Li ZH; Song YK; Wang JY; Tian YS; Liu DW; Yan X; Jiang L; Yang ZY; Chu JP
J Neurooncol; 2019 Jan; 141(1):195-203. PubMed ID: 30414095
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
